Loading candles…
Aurobindo Pharma is active in the development, manufacturing, and commercialization of a broad range of pharmaceutical products, including active pharmaceutical ingredients and generic medications. Operating within the pharmaceuticals, generic pharmaceuticals, and active pharmaceutical ingredients industries, the company serves markets in over 150 countries, notably the United States. It is recognized as the largest generic pharmaceutical company in the US by prescriptions dispensed and the second-largest listed Indian pharmaceutical company by revenue. Its operations include 29 commercial manufacturing facilities and 9 research and development centers. Aurobindo Pharma maintains extensive vertical integration to manage costs and enhance supply chain reliability. The company’s business segments encompass active pharmaceutical ingredients, generic pharmaceuticals, and related services.
This page is a live market overview for AUROBINDO PHARMA LTD (AUROPHARMA) on the NSE. As a listed security, AUROBINDO PHARMA LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for AUROPHARMA before placing trades on tick2trade.
As of the latest feed, AUROPHARMA last traded at ₹1,658 on NSE, up ₹69.1 (4.35%) from the previous close of ₹1,588.9. Today's session range is ₹1,579.9 – ₹1,662.4, against a 52-week band of ₹1,016.1 – ₹1,662.4. Traded volume today stands at 20.01L shares.
The overview consolidates an interactive price chart with multiple time ranges, a near-the-money option chain snapshot, recent market headlines, upcoming corporate events for AUROPHARMA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether AUROPHARMA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for AUROBINDO PHARMA LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in AUROPHARMA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated AUROPHARMA option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 5 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 21 May 2026 |
| Buyback | To consider buyback for equity shares | 6 Apr 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 9 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 5 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and dividend | 4 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 26 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.